Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nauheim – page 54

1 333 clinical trials in Bad Nauheim, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nauheim at a glance
1 333
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 333 trials in Bad Nauheim

Open in trial search

Psoriasis

Not recruiting

ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORKA-001
  • Sponsor:Oruka Therapeutics Inc.

Obesity

Not recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enicepatide
  • Sponsor:F. Hoffmann-La Roche AG

Rheumatoid arthritis

Not recruiting

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Obesity

Not recruiting

Efficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Berobenatide
  • Sponsor:Metsera Inc.

Obesity

Not recruiting

A study to evaluate the efficacy and safety of MET097 in people with obesity or overweight.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Berobenatide
  • Sponsor:Metsera Inc.

Dermatitis atopic

Not recruiting

A study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Uveal melanoma

Not recruiting

A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Darovasertib
  • Sponsor:Ideaya Biosciences Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nauheim

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on hypertrophic cardiomyopathy treatments, including trials of mavacamten and aficamten. Research also covers advanced therapies for heart failure and pulmonary hypertension management.

  • Cardiac Structure Improvement
  • Heart Function Enhancement
  • Pulmonary Hypertension Treatment

Long-term safety and efficacy evaluations of novel cardiovascular medications are prioritized.

02 Oncology Studies

Advanced research in breast cancer treatment, particularly focusing on HER2-negative and triple-negative variants. Studies evaluate innovative combination therapies including atezolizumab and targeted treatments.

  • Neoadjuvant Therapies
  • Immunotherapy Applications
  • Treatment Resistance

Emphasis on improving survival rates and reducing recurrence in early-stage breast cancer.

03 Inflammatory Conditions

Clinical investigations of inflammatory diseases including myositis and arteritis. Studies evaluate new biological treatments and their long-term effectiveness in managing chronic inflammatory conditions.

  • Autoimmune Disorders
  • Novel Biologics
  • Disease Modification

Focus on developing targeted therapies for better disease control and improved patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.